GlaxoSmithKline and Merck: private-sector collaboration for the elimination of lymphatic filariasis.
More than 1000 million people in 82 countries are at risk of contracting the tropical disease lymphatic filariasis (LF). Although the disease is wide-spread, transmission of the causative parasites can be stopped through mass drug administrations based on a combination of anti-parasitic medicines. For more than 10 years, the pharmaceutical companies GlaxoSmithKline (GSK) and Merck & Co., Inc., have participated in a unique private-sector collaboration to support the global efforts to eliminate LF, through donations of drugs to prevent the disease. GSK's albendazole and Merck's ivermectin (Mectizan) now reach hundreds of millions of people each year, through national LF-elimination programmes carried out in collaboration with Ministries of Health, the World Health Organization, non-governmental organizations and local communities. Working in support of the Global Programme to Eliminate Lymphatic Filariasis, GSK and Merck not only provide donated medicines but also offer financial, programmatic and management expertise to support LF-elimination efforts worldwide.
Gustavsen
K M
KM
Global Public Policy and Corporate Responsibility, Merck & Co., Inc, One Merck Drive, PO Box 100, WS 2A-56, Whitehouse Station, NJ 08889-0100, USA. ken_gustavsen@merck.com
Bradley
M H
MH
Wright
A L
AL
D015766:Albendazole / Q000600:supply & distribution / Q000627:therapeutic use*; D004345:Drug Industry; D004605:Elephantiasis, Filarial / Q000188:drug therapy* / Q000191:economics / Q000517:prevention & control; D005369:Filaricides / Q000600:supply & distribution / Q000627:therapeutic use*; D014943:Global Health; D006801:Humans; D007559:Ivermectin / Q000600:supply & distribution / Q000627:therapeutic use*; D017149:Private Sector; D015397:Program Evaluation
D005369:Filaricides; D007559:Ivermectin; D015766:Albendazole